T1	Disorder 6 27	peripheral neuropathy
N1 	Reference T1 UMLS:C0031117	peripheral neuropathy
T2	Pharmacological_substance 174 185	fludarabine
N1000 	Reference T2 MeSH:C024352	fludarabine
T3	Pharmacological_substance 190 200	cytarabine
N1001 	Reference T3 MeSH:D003561	cytarabine
T4	Pharmacological_substance 221 232	fludarabine
N1002 	Reference T4 MeSH:C024352	fludarabine
T5	Pharmacological_substance 237 247	cytarabine
N1003 	Reference T5 MeSH:D003561	cytarabine
T6	Disorder 288 296	toxicity
N2 	Reference T6 UMLS:C0600688	toxicity
T8	Pharmacological_substance 363 368	Ara-C
N1004 	Reference T8 MeSH:D003561	Ara-C
N1005 	Reference T8 MeSH:D003561	Ara-C
T10	Pharmacological_substance 415 431	antifungal agent
N1006 	Reference T10 MeSH:D000935	antifungal agent
T11	Disorder 519 540	neurological toxicity
N3 	Reference T11 UMLS:C0600688	neurological toxicity
T9	Disorder 91 140	progressive peripheral neurological deterioration
N4 	Reference T9 UMLS:C1457868	progressive peripheral neurological deterioration
N5 	Reference T9 UMLS:C1457868	progressive peripheral neurological deterioration
T15	Pharmacological_substance 380 392	chemotherapy
N1007 	Reference T15 MeSH:C403362	chemotherapy
N1008 	Reference T15 MeSH:D004113	chemotherapy
N1009 	Reference T15 MeSH:C057647	chemotherapy
T18	Combination 186 189	and
T16	Pharmacological_substance 216 219	FLA
N1010 	Reference T16 MeSH:D005408	FLA
T14	Pharmacological_substance 339 342	FLA
N1011 	Reference T14 MeSH:D005408	FLA
T17	Speculation_cue 505 509	risk
T7	Pharmacological_substance 38 41	FLA
N1012 	Reference T7 MeSH:D005408	FLA
